Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | GLI1 | P08151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28234838 | 1.00 | CTSC (0.39) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL19750647 | 1.00 | CTSC (0.39) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL3511447 | 1.00 | CTSC (0.39) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL30530762 | 0.98 | CTSC (0.39) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL14665843 | 0.82 | CTSC (0.40) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7361978 | 0.82 | CYP2D6 (0.52) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7338708 | 0.82 | CYP2D6 (0.52) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL689400 | 0.82 | CYP2D6 (0.52) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL1269918 | 0.82 | CYP2D6 (0.52) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7338717 | 0.82 | CYP2D6 (0.52) | CTSCCYP1A2CYP2D6ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670228-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-03-23 | — | — | US | disclosed |
| US-9546178-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20160052933-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-02-25 | — | — | US | disclosed |
| US-9198918-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-8785626-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586574-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8343955-B2 | Benzoxazepin PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2012-09-27 | — | — | US | disclosed |
| US-8242104-B2 | Benzoxazepin P13K inhibitor compounds and methods of use | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140058098-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20120244149-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20140288047-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20130079331-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20160052933-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20110076292-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
| US-20170081341-A1 | BENZOXAZEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BMX, PIK3CA, PI4KA | CTSC 3728/4885CYP1A2 1145/4885CYP2D6 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.